{"id":6149,"date":"2022-09-18T12:13:41","date_gmt":"2022-09-18T07:43:41","guid":{"rendered":"http:\/\/arasto.com\/product\/celecoxib\/"},"modified":"2023-05-06T12:39:09","modified_gmt":"2023-05-06T09:09:09","slug":"celecoxib","status":"publish","type":"product","link":"https:\/\/arasto.com\/fa\/product\/celecoxib\/","title":{"rendered":"Celecoxib"},"content":{"rendered":"

Description<\/strong><\/p>\n

(USP 44)<\/p>\n

    \n
  1. Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n

    1.1. Nomenclature (ICH 3.2.S.1.1)<\/strong><\/p>\n

    International non-proprietary name:\u00a0 Celecoxib (Brand Name: Celebrex, Celebra)<\/p>\n

    Compendial name:\u00a0 Celecoxib<\/p>\n

    Chemical name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl] benzenesulfonamide<\/p>\n

    Arasto\u2019s code:\u00a0 CEL<\/p>\n

    CAS Registry Number: [169590-42-5]<\/p>\n

      \n
    1. Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n

      1.2. Structure (ICH 3.2.S.1.2)<\/strong><\/p>\n

      <\/p>\n

      Empirical formula: C17<\/sub>H14<\/sub>F3<\/sub>N3<\/sub>O2<\/sub>S<\/p>\n

      Molecular Weight: 381.38 g\/mol<\/p>\n

        \n
      1. Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n

        1.3. General Properties (ICH 3.2.S.1.3)<\/strong><\/p>\n

        Celecoxib is a white to off-white crystalline substance.\u00a0 It is orally administered for the treatment of pain associated with osteoarthritis rheumatoid, arthritis juvenile rheumatoid, arthritis ankylosing, and acute pain as well as spondylitis and primary dysmenorrhea.\u00a0 It is insoluble in water and soluble in all organic solvents except linear and branched alkanes (hexane, heptane, etc.)It is soluble in water at high alkaline pH due to sulfonamide salt formation (pKa<\/sub>= 11.1,\u00a0www.pfizer.ca<\/a>, Product Monograph). Its log P has been reported to be 3.47 (http:\/\/www. chemicalland21.com\/lifescience\/phar\/CELECOXIB).\u00a0 Celecoxib is relatively inert to acid and base (see Stability Studies). Oral LD50<\/sub>\u00a0of Celecoxib has been reported to be greater than 2000 mg\/kg in the rat (http:\/\/web.ncifcrf.gov\/rtp\/LASP\/intra\/forms\/msds\/msds_Celecoxib).<\/p>\n

        The determination of purity and assay of APIs require comparison of the product with their respective Reference Standards (RS) and Related Compounds (RC or known impurities).\u00a0 Accordingly, ICH regulations on the purity and assay of reference standard and related compounds are clearly defined and must be followed by drug substance and drug product manufacturers.<\/p>\n

        According to ICH Q7, 11.1 there are 3 types of standards.\u00a0 This is summarized in the following chart and discussed in detail below.<\/p>\n

        <\/p>\n

        The impurities provided in the following table represent Secondary Reference Standards (SRS) that are prepared in-house by synthesis or by isolation.\u00a0Each SRS has undergone extensive characterization ( IR, UV, 1HNMR, 13CNMR. Mass Spec) and determination of its purity and assay (HPLC).\u00a0For specification of the SRS of those products that have a monograph, the SRS is compared with a pharmacopoeia Primary Reference Standard (UV, HPLC retention time).\u00a0For specification of those products that do not have a monograph (known as House Primary Standard), we compare their UV \u03b5 or \u05d2 \/max<\/sub>, IR major absorptions, 1HNMR d (ppm) , 13 CNMR d (ppm) or HPLC retention time with values reported in the chemical literature for these compounds.<\/p>\n

        \u00a0<\/strong><\/p>\n

        Celecoxib Related Compounds<\/strong><\/p>\n\n\n\n\n\n
        Structure<\/strong><\/td>\nChemical Name<\/strong><\/td>\nUSP Code<\/strong><\/td>\nUSP <\/strong><\/p>\n

        Code<\/strong><\/td>\n<\/tr>\n

        <\/td>\n(4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide)<\/td>\nCelecoxib<\/p>\n

        RC A<\/td>\n

        		Celecoxib<\/p>\n

        RC A<\/td>\n<\/tr>\n

        <\/td>\n(4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide)<\/td>\nCelecoxib<\/p>\n

        RC B<\/td>\n

        		Celecoxib<\/p>\n

        RC B<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

          \n
        1. Primary and Secondary Reference Standard (ICH 3.2.S.5)<\/strong><\/li>\n<\/ol>\n

          5.1.\u00a0Active Pharmaceutical Ingredient<\/strong><\/p>\n

          Primary Reference Standard for Celecoxib is available from United States Pharmacopoeia. We will use a Secondary Reference Standard (previously referred to as Working Standard) for direct control of all batches of Celecoxib.<\/p>\n

          As per ICH (Q7, 11.1) and ICH (Q6, 2.11, 3.2, 3.3)House Primary \u00a0Standards, which include the API and its Related Compounds,\u00a0must be examined for their proof of structure (characterization), assay and purity and specification (identification by comparison). Furthermore, ICH Guideline on the Preparation of Common Technical Document (Q4M) requires that the data obtained from characterization, assay and purity and specification must be included in section 3.2.S.3.2 for Related Compounds (already discussed in that section) and section 3.2.S.5 of the DMF for the API.\u00a0To this end, the House Primary Standard of the API celecoxib has undergone extensive characterization (UV, IR,\u00a01<\/sup>\u00a0H NMR,\u00a013<\/sup>C NMR, Mass Spec) to assure its structure, assay and purity (HPLC and\/or titration) and specification .<\/p>\n

          The Secondary Reference Standard for Celecoxib was produced from a released batch of Celecoxib by subjecting it to an additional crystallization from the final solvent system used in the production of the API to avoid the possibility of other polymorph formation.<\/p>\n

          SPECIFICATION OF ANALYSIS<\/h1>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
          Product:<\/strong> Celecoxib<\/td>\nCAS No.: <\/strong>169590-42-5<\/td>\nSpec. No.: <\/strong>APC-QC-SPEC-240-00<\/td>\n<\/tr>\n
          Issue Date: <\/strong>Apr, 2023<\/td>\nValid up to:<\/strong> Apr, 2024<\/td>\nReference: <\/strong>USP44<\/td>\n<\/tr>\n
          Tests<\/strong><\/td>\n\n

          Specifications<\/h2>\n<\/td>\n<\/tr>\n

          Description<\/td>\nWhite or almost white, crystalline or amorphous powder.<\/td>\n<\/tr>\n
          Solubility<\/td>\nSoluble to freely soluble in ethanol; Soluble in methylene chloride. Practically insoluble in water.<\/td>\n<\/tr>\n
          Identification<\/td>\nA) Infrared Spectroscopy<\/p>\n

          B) The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the assay.<\/td>\n<\/tr>\n

          Water determination<\/td>\nNMT 0.5%<\/td>\n<\/tr>\n
          Residue on ignition<\/td>\nNMT 0.2% (using a platinum crucible)<\/td>\n<\/tr>\n
          Residual Solvents<\/td>\nMethanol: Max 3000ppm (Class II)<\/td>\n<\/tr>\n
          Organic Impurities (HPLC)<\/td>\nCelecoxib Related Compound A: NMT 0.4%<\/p>\n

          Celecoxib Related Compound B: NMT 0.10%<\/p>\n

          Individual unspecified impurity: NMT 0.10%<\/p>\n

          Total impurities: NMT 0.5 %<\/td>\n<\/tr>\n

          Assay (HPLC)<\/td>\n98.0% to 102.0% (on the anhydrous basis)<\/td>\n<\/tr>\n
          Prepared by:<\/strong> M. Shahbazi, B.Sc.Chem.<\/td>\nChecked by:<\/strong> A. Forghani, B.Sc.Chem.<\/td>\n<\/tr>\n
          Approved by:<\/strong> F. Javadizadeh, M.Sc.Chem.<\/td>\n<\/tr>\n
          Storage:<\/strong> Preserve in tight containers, protected from light and moisture. Store at room temperature.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

          Description (USP 44) Drug Substance General Information (ICH 3.2.S.1) 1.1. Nomenclature (ICH 3.2.S.1.1) International non-proprietary name:\u00a0 Celecoxib (Brand Name: Celebrex, Celebra) Compendial name:\u00a0 Celecoxib Chemical name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl] benzenesulfonamide Arasto\u2019s code:\u00a0 CEL CAS Registry Number: [169590-42-5] Drug Substance General Information (ICH 3.2.S.1) 1.2. Structure (ICH 3.2.S.1.2) Empirical formula: C17H14F3N3O2S Molecular Weight: 381.38 g\/mol Drug Substance General […]<\/p>\n","protected":false},"featured_media":7123,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_cat":[72],"product_tag":[],"class_list":["post-6149","product","type-product","status-publish","has-post-thumbnail","hentry","product_cat-72"],"_links":{"self":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/comments?post=6149"}],"version-history":[{"count":2,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6149\/revisions"}],"predecessor-version":[{"id":7127,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6149\/revisions\/7127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/media\/7123"}],"wp:attachment":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/media?parent=6149"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product_cat?post=6149"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product_tag?post=6149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}